Skip to contentpdufa.bio

AP02 (inhaled nintedanib)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

AP02 (inhaled nintedanib) is an Avalyn Pharma Inc. program in idiopathic pulmonary fibrosis (IPF). Its next catalyst is a Readout in Q4 2027.

AVLN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: idiopathic pulmonary fibrosis (IPF). Sponsor: Avalyn Pharma Inc. (AVLN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027AVLN

Specialist biotech funds holding AVLN, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors350,000$10.0 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is AP02 (inhaled nintedanib)'s next FDA decision or readout?

The next tracked catalyst for AP02 (inhaled nintedanib) is a Readout in Q4 2027.

What happened at AP02 (inhaled nintedanib)'s most recent FDA decision?

No FDA decision for AP02 (inhaled nintedanib) is in our archive yet.

What is AP02 (inhaled nintedanib) used for?

In our records AP02 (inhaled nintedanib) is under review or in development for idiopathic pulmonary fibrosis (IPF).

Who makes AP02 (inhaled nintedanib)?

Avalyn Pharma Inc. (AVLN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.